About Anti-Nuclear Antibody (ANA) Testing
Antibodies that attack healthy proteins in the nucleus cells are called antinuclear antibodies. When a person has an autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus (SLE), the immune system produces antibodies that will attach to the cells, often causing damage to them. Some of the ANA tests are EUROPLUS ANA Mosaic 20A, QUANTA Lite ANA, BioPlex 2200 ANA Screen. The global ANA testing market is expected to benefit from the growing incidence of several autoimmune diseases worldwide.
Technavio’s analysts forecast the global anti-nuclear antibody (ANA) testing market to grow at a CAGR of 7.13 % during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global anti-nuclear antibody (ANA) testing market for 2017-2021. To calculate the market size, the report considers the new installations/sales/volume/value and replacement/ services of anti-nuclear antibody testing market.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Anti-Nuclear Antibody (ANA) Testing Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Abbott Laboratories
• Alere
• Bio-Rad Laboratories
• Thermo Fisher Scientific
Other prominent vendors
• Antibodies Incorporated
• Biocom Biotech
• Erba Diagnostics
• F. Hoffmann-La Roche
• HOB Diagnostics
• HUMAN Diagnostics
• IMMCO
• ImmunArray
• Phadia
• Seramun Diagnostica
• Trinity Biotech
Market driver
• Increased prevalence of autoimmune diseases
• For a full, detailed list, view our report
Market challenge
• Limitations of autoimmune disease diagnostics
• For a full, detailed list, view our report
Market trend
• Shift from monoplex to multiplex testing
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Market segmentation by end-user
• Hospitals
• Clinical diagnostic laboratories
PART 07: Geographical segmentation
• ANA testing market in Americas
• ANA testing market in EMEA
• ANA testing market in APAC
PART 08: Decision framework
PART 09: Drivers and challenges
• Market drivers
• Market challenges
PART 10: Market trends
• Shift from monoplex to multiplex testing
• Collaborations between pharma and diagnostic companies
• Growing consumer shift toward direct-to-consumer testing
PART 11: Vendor landscape
• Competitive scenario
PART 12: Key vendor analysis
• Abbott Laboratories
• Alere
• Bio-Rad Laboratories
• Thermo Fisher Scientific
• Other prominent vendors
PART 13: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Etiology of autoimmune diseases
Exhibit 02: Global ANA testing market 2016-2021: Market outline
Exhibit 03: Key trends in global autoimmune disease diagnostics market: Impact assessment
Exhibit 04: Global ANA testing market 2016-2021 ($ millions)
Exhibit 05: Five forces analysis
Exhibit 06: Global ANA testing market by end-users: Overview
Exhibit 07: Global ANA testing market by end-users: Impact assessment
Exhibit 08: Global ANA testing market by geography 2016 (%)
Exhibit 09: ANA testing market in Americas 2016-2021: Overview
Exhibit 10: ANA testing market in Americas 2016-2021 ($ millions)
Exhibit 11: ANA testing market in EMEA 2016-2021: Overview
Exhibit 12: ANA testing market in EMEA 2016-2021 ($ millions)
Exhibit 13: ANA testing market in APAC 2016-2021: Overview
Exhibit 14: ANA testing market in APAC 2016-2021 ($ millions)
Exhibit 15: Incidence estimates of type 1 diabetes, children aged 0–14 years, 2014
Exhibit 16: Key initiatives of vendors fueling the launch of novel biomarkers
Exhibit 17: Competitive structure analysis of global ANA testing market 2016
Exhibit 18: Competitive landscape analysis of global ANA testing market 2016
Exhibit 19: Strategic success factors of companies in global ANA testing market
Exhibit 20: Abbott Laboratories: Key highlights
Exhibit 21: Abbott Laboratories: Strength assessment
Exhibit 22: Abbott Laboratories: Strategy assessment
Exhibit 23: Abbott Laboratories: Opportunity assessment
Exhibit 24: Alere: Key highlights
Exhibit 25: Alere: Strength assessment
Exhibit 26: Alere: Strategy assessment
Exhibit 27: Alere: Opportunity assessment
Exhibit 28: Bio-Rad Laboratories: Key highlights
Exhibit 29: Bio-Rad Laboratories: Strength assessment
Exhibit 30: Bio-Rad Laboratories: Strategy assessment
Exhibit 31: Bio-Rad Laboratories: Opportunity assessment
Exhibit 32: Thermo Fisher Scientific: Key highlights
Exhibit 33: Thermo Fisher Scientific: Strategy assessment
Exhibit 34: Thermo Fisher Scientific: Strategy assessment
Exhibit 35: Thermo Fisher Scientific: Opportunity assessment
